The Latest Breaking News on Pharma

Canada’s Families Minister Karina Gould reacted to the US legal battle over mifepristone the day before the US Supreme Court ruling

WASHINGTON — The U.S. Supreme Court blocked a Texas judge’s restrictions on a widely used abortion pill from taking effect, keeping the drug fully available while a legal fight goes forward.

Federal judge in Texas ruled in early April to suspend FDA-approved mifepristone used in more than half of abortions in US

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

The biopharmaceutical industry has been grappling with various challenges, including inflation, the Fed’s hawkish stance, and new regulatory concerns. Hence, it could be wise to avoid Syndax Pharmaceuticals (SNDX), Senseonics Holdings (SENS), and Sio Gene Therapies (SIOX) due to their bleak fundamentals. Keep reading….

Depression drug stock Intra-Cellular Therapies is up over 14% in April and 36% since mid-March.

Coupled with fears about an economic downturn, several other headwinds could keep the biotechnology industry under significant pressure. Given this backdrop, fundamentally weak biotech stocks Day One Biopharmaceuticals (DAWN), Northwest Biotherapeutics (NWBO), and Ocugen (OCGN), with bearish momentum, could be avoided in April. Read on….

Novavax has a solid platform but continues to face a $700 million litigation headwind, an analyst said Thursday as he downgraded NVAX stock.

WASHINGTON — The Supreme Court gave itself more time on a decision expected Wednesday about a commonly used abortion drug, extending until Friday a temporary pause on a lower court ruling that would restrict availability of mifepristone.

A generic-mifepristone maker sued the U.S. Food and Drug Administration to protect access to the medical abortion pill amid a welter of litigation stretching from Texas to Washington.

The court has given itself until Friday to rule on whether to allow restrictions to take effect on mifepristone as legal challenges to its FDA approval continue.